#1Operate in the Now August 2, 2022 JUUSINS SeaSpine#2Forward-looking Statements & Disclaimer This presentation includes statements that may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "estimate," "expect," "anticipate," "project," "forecast" and similar expressions, or the negative thereof, among others, generally identify forward-looking statements. Forward- looking statements used in this presentation include revenue guidance; future revenue and revenue growth; liquidity to fund growth; new product launches and market opportunity, market share and market share growth. SeaSpine® cautions that these forward-looking statements are based on management's current expectations, estimates, forecasts and projections, and assumptions management believes are reasonable, and are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ongoing impact of the COVID-19 pandemic on the elective surgery market and the global healthcare system generally; risks that the COVID-19 pandemic may disrupt the Company's business and/or the global healthcare system more severely than anticipated; surgeons' willingness to use the Company's existing and newly launched products; the Company's ability to continue to invest in medical education and training, product development, and/or sales and marketing initiatives at levels sufficient to drive future revenue growth; the Company's ability to attract new, high-quality distributors and potential disruption to the Company's sting distribution network; continued pricing pressure, as well as exclusion from major healthcare systems; the risk of supply shortages and the associated, potentially long-term disruption to product sales; unexpected expense and delay; changes to laws and regulations applicable to the Company and the industry in which it competes; and general economic and business conditions in the markets in which the Company does business, both in the U.S. and abroad. Additional information about the factors that may affect the operations of SeaSpine and results is set forth in SeaSpine's annual and quarterly reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this presentation are made only as of the date set forth on the cover hereof and SeaSpine undertakes no obligation to release publicly any revisions or updates to forward-looking statements as a result of subsequent events or developments, except as required by law. Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 2 SeaSpine#3Sea Beyond SeaSpineⓇ is uniquely transforming the OR with safe, fast, real-time solutions that give surgeons & hospital partners confidence and deliver better outcomes to improve patient lives - NOW. Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 3 SeaSpine#4333 Spinal Implants & Fixation Enabling Technologies SeaSpine. Orthobiologics Transformative Solutions at Every Level. In Real-time Operate in the Now. Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 4 SeaSpine#57D Surgical Navigation Unique Value Proposition Leading the charge in accuracy, safety and hospital economic benefit TO FLASH™ REGISTRATION 75 SEGMENTAL REGISTRATION RADIATION- FREE FOR OPEN PROCEDURES & SURGEON CONTROL $ FLEXIBLE PURCHASE OPTIONS Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 5 INTEGRA ad Data threshold FLASH F Se Register Trajectory 3% + Bolory .. Check Poi 8 BARCO 6 60 mm -50 mm 100 mm 8 SeaSpine#6FLASH NAVIGATION 70 Technology SeaSpine Addressing >$2B of New Market Segments FOUNDATIONAL PRODUCTS Expected to Drive Double-Digit Growth Differentiated, biologic-friendly spinal implants and advanced orthobiologics coupled with market leading image guidance enabling technology Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 6 SeaSpine#7FLASH NAVIGATION 70 Technology with SeaSpine FLASH™ Navigation with 7D Technology MarinerⓇ Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 7 SeaSpine#8Surface Technologies NanoMetaleneⓇ Reef TopographyⓇ WaveformⓇ Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 8 SeaSpine#943-0101010 0,001OF OF 78748 43-00100001 FLASH NAVIGATION 70 Technology SeaSpine NorthStar® OCT NorthStar™ Facet Fusion Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 9 PACH GUIDE B-6090203.001 SeaSpine#10720 30 Admiral™ ACP OsteoStrand® Plus Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 10 SeaSpine#11BEST-IN-CLASS Advanced DBMs Investment in peer-reviewed science and education supporting improved clinical value vs. traditional DBMS and more expensive cellular products (Abedi et al JBJS, Russell et al Frontiers 2020) ©2022 SeaSpine Orthopedics Corporation. All rights reserved | 11 16 SeaSpine#12Dry is Better OsteoTorrent/C Dry DBM Putty Family Designed to improve bone forming capacity/inductivity and shelf-life stability Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 12 SeaSpine#13Nano Metalene surfacing with to promote Endplate & aperture undercut macrostructures to promote bony interlocking FUSION Deliberate Design. Driven by Science. ENGINEERED Opposing slots for axial stability 1mm depth to balance bone-to-implant integrity Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 13 Sea Spine#14Shaeffer Bannigan Vice President Product Development Bill Rhoda General Manager of Process Innovation & Development John Bostjancic Chief Operating & Financial Officer Beau Standish, PhD, PEng President Enabling Technologies. Keith C. Valentine President & Chief Executive Officer Dennis Cirino Senior Vice President Global Spinal Systems Frank Vizesi, PhD Chief Scientific Officer Laetitia Cousin Vice President Regulatory & Quality Assurance Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 14 John Winge Vice President Sales Patrick Keran Senior Vice President Corporate Development & General Counsel & Corporate Secretary wane Hollis Winkler Senior Vice President Human Resources Senior Leadership Team An assembly of experienced leadership driving vision forward with 230+ years in spine/orthopedics Tyler Lipschultz Senior Vice President Orthobiologics & Business Development SeaSpine#15Partnerships Vital to Executing Our Vision Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 15 40*40 B Sea Spine#16Partnerships Expansion for Efficient Revenue Growth Large distributor conversions Direct sales force in key white space markets Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 16 Sea Spine#17Surgeon Education Market Development VALUE Sales Training MEDICAL EDUCATION PROGRAMS Furthering our commitment to our partners 150+ COAST visits, trainings, labs 250+ Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 17 Cases Supported (alpha cases, new users & complex case support) SeaSpine#18$ $56.3M Total Revenue (an increase of 19% YoY) $24.5M US Orthobiologics Revenue (an increase of 16% YoY) ($) $49.5M US Revenue (an increase of 16% YoY) Livi 66.0% 67.9% ADJUSTED Gross Margin GAAP $25.0M US Spinal Implants & Enabling Technologies Revenue (an increase of 17% YoY) APRI $ $66.1M Liquidity Cash at 6/30/22 Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 18 Q2 Highlights 2022 Financial Results SeaSpine#190 A Full Commercial Launch ReefⓇ TA Explorer TO Expandable IBD Osteo Torrent™M/OsteoTorrent C WaveFormⓇ TO WaveForm® C MeridianⓇ H Limited Commercial Launch FLASHTM Navigation Lumbar Facet Fusion Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 19 Product Highlights 2022 Product Innovation SeaSpine#201+1 $234-236M FY 2022 Revenue (22-23% Growth) 11-12% R&D Expense as % of Total Revenue 150-200BPS Adj. GM % Expansion (65.2-65.7%) oin $3.5-4.5M Adj. EBITDA Loss Reduction (15-20%) Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 20 Guidance 2022 Financial guidance information is as of August 2, 2022, based on guidance provided by SeaSpine leadership on that date. Inclusion of this information in this presentation is not a confirmation or an update of, and should not be construed or otherwise assumed to reflect any confirmation or update of, that guidance by SeaSpine leadership as of any date other than August 2, 2022. Adjusted Gross Margin and Adjusted EBITDA Loss are non-GAAP financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. These non-GAAP financial measures should not be considered a replacement for, and should be read together with, the most directly comparable GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in Appendix A to this presentation. SeaSpine#21● ● +15 Product Launches & Line Extensions WaveForm® 3D IBD Explorer® Expandable IBD Mariner® Adult Deformity MIS Navigation Integrated FLASH™ Navigation tools OsteoTorrent™ DBMS Meridian >$60M Free Cash Flow Burn >$42M Investment in Inventory & Spinal Implant Sets >$2M Outflow on Final EMEA SI Stocking Orders - C 3 YEAR Extension of Credit Facility & $10M Expansion & Completed July 2022 Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 21 Guidance 2022 Financial guidance information is as of August 2, 2022, based on guidance provided by SeaSpine leadership on that date. Inclusion of this information in this presentation is not a confirmation or an update of, and should not be construed or otherwise assumed to reflect any confirmation or update of, that guidance by SeaSpine leadership as of any date other than August 2, 2022. SeaSpine#22$ 15-18% 3-year Revenue CAGR om 150BPS Commission Leverage by 2024 (vs. 2019) S $300- $320M Annual Revenue Threshold for Adj. EBITDA Breakeven (exiting 2024) 10% R&D Expense as % of Total Revenue in 2024 Q >500BPS Adj. GM % Expansion by 2024 $ >50% Reduction in Free Cash Flow Burn by 2024 Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 22 Guidance Long-Term Financial guidance information is as of August 2, 2022, based on guidance provided by SeaSpine leadership on that date. Inclusion of this information in this presentation is not a confirmation or an update of, and should not be construed or otherwise assumed to reflect any confirmation or update of, that guidance by SeaSpine leadership as of any date other than August 2, 2022. SeaSpine#23$250.0 $200.0 $150.0 $100.0 $50.0 FINANCIAL HIGHLIGHTS Accelerating Revenue Growth 2015 -3% 2016 2% 2017 Total Revenue ($ in millions) 9% 2018 Total Revenue 11% 2019 Revenue Growth n -3% Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 23 2020 2022 represents the mid-point of FY 2022 revenue guidance of $234-$236M. 24% 2021 22% 2022 30% 25% 20% 15% 10% 5% 0% -5% -10% SeaSpine#24↑ Innovative Procedural Solutions and Enabling Technologies -O Expanding Network of Highly Competitive Distributors EJ Improved Clinical Outcomes and Economic Value ŁA $ Capitalized to Execute Strategy Investment Highlights Best-in-Class Product Portfolio + Expanding Distribution to Grow 5x the Market Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 24 SeaSpine#25THANK YOU Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 25 SeaSpine#26Total revenue, net Less: Cost of goods sold Gross profit Add back: APPENDIX A Reconciliation of Non-GAAP to GAAP Financial ($ in millions) Technology-related intangible asset amortization Fixed NanoMetalene supplier processing charge Purchase accounting inventory fair market value adjustments Idle manufacturing plant costs Adjusted gross profit Adjusted gross margin (Adjusted gross profit/Total revenue, net) ($ in millions) GAAP net loss Non-GAAP adjustments Depreciation and intangible asset amortization expense Other (income) expense Income tax (benefit) provision Fixed NanoMetalene supplier processing charge Idle manufacturing plant costs Spinal set instrument replacement expense Spinal set instrument impairment expense Stock-based compensation Impairment on intangible assets European sales and marketing organization restructuring Purchase accounting inventory fair market value adjustments Acquisition and integration-related charges Total Non-GAAP adjustments Adjusted EBITDA loss $ $ $ $ $ Q1 20 36.111 $ 13.812 22.299 0.294 22.593 $ 62.6% Q1 20 (12.551) $ 2.608 $ (0.227) 0.035 0.379 0.2 1.983 1.325 6.337 $ (6.214) $ Q2 20 28.589 $ 11.659 16.930 0.241 0.974 18.145 63.5% $ Q2 20 (13.713) $ 2.608 $ (0.014) 0.033 0.974 0.551 (0.024) 2.769 6.897 $ (6.816) $ Q3 20 43.209 $ 14.074 29.135 0.254 29.389 $ 68.0% Q3 20 (6.574) $ 2.713 $ (0.136) 0.064 0.625 3.182 6.448 $ (0.126) $ Q4 20 46.436 $ 17.296 29.140 0.257 29.397 63.3% Q4 20 (10.343) $ $ 2.796 $ (0.086) 0.086 1.244 2.423 6.463 $ (3.880) $ Q1 21 41.954 $ 15.366 26.588 0.267 26.855 $ 64.0% 2.747 $ 0.159 0.025 0.730 Q1 21 Q2 21 (12.720) $ (5.213) $ 2.546 Q2 21 47.463 $ 17.482 29.981 1.276 7.483 $ (5.237) $ 0.609 30.590 $ 64.5% 3.133 $ (6.079) 0.158 0.915 3.096 0.519 1.742 $ (3.471) $ Q3 21 Q4 21 Q1 22 46.445 $ 55.589 $ 50.693 $ 18.289 25.727 20.376 28.156 29.862 30.317 1.291 0.417 29.864 $ 34.242 $ 64.3% 61.6% 4.400 $ 0.231 (0.872) 1.020 0.551 3.704 0.125 3.149 1.665 0.417 0.200 10.210 $ (7.417) $ Q3 21 Q4 21 Q1 22 (17.627) $ (18.786) $ (16.604) $ 3.653 $ 0.157 (0.411) 3.704 1.239 Financial Measures Measures 3.065 0.161 0.125 0.305 11.998 $ (6.788) $ 0.986 0.125 31.428 $ 62.0% 4.202 $ (0.002) (0.228) 1.018 2.819 0.279 0.125 0.372 8.585 $ (8.019) $ Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 26 Q2 22 56.318 19.127 37.191 0.986 0.083 38.260 67.9% Q2 22 (13.947) 4.295 0.559 (1.147) 1.665 3.701 0.127 0.083 (0.010) 9.273 (4.674) In addition to financial measures reported in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"), the Company provides two non-GAAP financial measures: (1) earnings (loss) before interest, taxes, depreciation and amortization excluding the impact of stock-based compensation, intangible asset impairment charges, the nonrecurring, fixed NanoMetalene supplier processing charge, idle manufacturing plants costs, spinal set instrument replacement and impairment expenses, other income/expense purchase accounting inventory fair market value adjustment charges, acquisition and integration-related charges, and employee severance and other charges related to the restructuring of the Company's European sales and marketing organization ("Adjusted EBITDA Loss"), and (2) gross margin excluding technology-related intangible asset amortization expense, purchase accounting inventory fair market value adjustment charges, the nonrecurring fixed NanoMetalene supplier processing charge, and idle manufacturing plant costs ("Adjusted Gross Margin"). The Company believes that the presentation of Adjusted EBITDA Loss and Adjusted Gross Margin provides important supplemental information to management and investors regarding financial and business trends relating to the Company's results of operations. Management uses Adjusted EBITDA Loss and Adjusted Gross Margin when evaluating operating performance because it believes that the inclusion or exclusion of the items described below, for which the amounts and/or timing may vary significantly depending upon the Company's acquisition and integration activities, for which the amounts are non-cash in nature, and/or for which the amounts are not expected to recur at the same magnitude, provides a supplemental measure of the Company's operating results that facilitates comparability of its financial condition and operating performance from period to period, against its business model objectives, and against other companies in its industry. The Company has chosen to provide this information to investors so they can analyze the Company's operating results in the same way that management does and use this information in their assessment of its core business and the valuation of the Company. Reconciliations of these non-GAAP financial measures to their nearest GAAP financial measures are provided in the tables to the left. For further information regarding our use of non-GAAP financial measures, please refer to the Current Report on Form 8-K that SeaSpine filed with the Securities and Exchange Commission on August 2, 2022. SeaSpine